Success Metrics

Clinical Success Rate

75.0%

Based on 6 completed trials

Completion Rate

75%(6/8)

Active Trials

0(0%)

Results Posted

117%(7 trials)

Terminated

2(25%)

Phase Distribution

Ph phase_4

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution1 total trials

Phase 4Post-market surveillance

1(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Terminated(2)

Detailed Status

Completed6

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 4

Trials by Phase

Phase 41 (100.0%)

Trials by Status

completed675%

terminated225%

Recent Activity

0 active trials

Showing 5 of 8

terminatedphase_4

ANTES B+ Clinical Trial

NCT06282861

completed

A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler

NCT03663569

completed

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

NCT05393245

completed

Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

NCT03954132

completed

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)

NCT03165045

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT06282861Phase 4

ANTES B+ Clinical Trial

Terminated

NCT03663569

A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler

Completed

NCT05393245

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Completed

NCT03954132

Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

Completed

NCT03165045

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)

Completed

NCT03003494

Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy

Completed

NCT02720757

Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)

Terminated

NCT02675517

Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8